September 2, 2022 — Dapagliflozin reduces the risk of cardiovascular death or worsening heart failure in heart failure patients with mildly reduced and preserved ejection fraction, according to late breaking researc

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients with acute decompensated heart failure, according to late breaking research presented in a Ho

September 2, 2022 — A randomized trial in more than 45,000 men has suggested that cardiovascular screening including cardiac imaging, blood pressure measurement and blood tests, plus treatment if needed, may lower the risk of death, heart attack and stroke in 65 to 69 year-olds.

September 2, 2022 — In an innovative, pragmatic randomized trial, high-dose influenza vaccination in older adults was associated with a reduction in the risk of death by 49% and in the incidence of hospitalization for 

September 2, 2022 — In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by artificial intelligence (AI) is superior to initial 

September 2, 2022 — Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe left ventricular dysfunction and extensive 

September 1, 2022 — “At ESC Congress in Barcelona, we discussed the newest science in the light of our collective clinical experience. This is how true progress in cardiovascular medicine is made,” said Professor Stephan Achenbach, ESC President. “The first double-blind randomized trial in cardiovascular medicine was completed in 1971, and since then, we have witnessed ever accelerating advances.

September 1, 2022 — A target blood pressure of 77 mmHg provides no benefit to survival or neurological outcome in comatose cardiac arrest survivors compared with a 63 mmHg target, according to late breaking research presented in a 

September 1, 2022 — The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischaemic heart disease, acco

August 31, 2022 — Medtronic plc, a global leader in healthcare technology, announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now